The Retatrutide 20mg Pen offers a high-concentration, ready-to-use delivery system for advanced research into multi-pathway obesity treatments and metabolic regulation. Retatrutide is a novel triple agonist peptide, activating GLP-1, GIP, and glucagon receptors, and is currently being investigated for its potential to outperform both Semaglutide and Tirzepatide in weight loss and insulin control models.
This 20mg pen is ideal for weekly dosing protocols, longitudinal metabolic studies, or professional administration under clinical supervision.
